TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prophase Labs ( (PRPH) ) has shared an announcement.
On November 24, 2025, ProPhase Labs, Inc. conducted a Special Meeting of Stockholders where six proposals were presented and approved. The proposals included acquiring digital assets, creating a new class of digital treasury shares, issuing digital tokens, and authorizing stock splits. Proposal 4, concerning stock splits, notably met the approval requirements for charter amendments under Delaware law, indicating strong shareholder support and potential strategic shifts for the company.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Underperform.
Prophase Labs faces significant financial and technical challenges, with declining revenues, negative profitability, and bearish technical indicators. The negative P/E ratio further highlights valuation concerns. While there are some strategic initiatives in place, the overall outlook remains weak, necessitating substantial improvements to enhance financial stability and investor confidence.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
ProPhase Labs, Inc. operates in the healthcare industry, focusing on developing and marketing products related to health and wellness.
Average Trading Volume: 1,994,578
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.3M
For detailed information about PRPH stock, go to TipRanks’ Stock Analysis page.